NZ581309A - Ion channel modulators and methods of use - Google Patents

Ion channel modulators and methods of use

Info

Publication number
NZ581309A
NZ581309A NZ581309A NZ58130908A NZ581309A NZ 581309 A NZ581309 A NZ 581309A NZ 581309 A NZ581309 A NZ 581309A NZ 58130908 A NZ58130908 A NZ 58130908A NZ 581309 A NZ581309 A NZ 581309A
Authority
NZ
New Zealand
Prior art keywords
pain
optionally substituted
compound
independently
acute
Prior art date
Application number
NZ581309A
Other languages
English (en)
Inventor
Esther Martinborough
Timothy Neubert
Tara Whitney
Danielle Lehsten
Tara Knoll
Nicole Zimmermann
Andreas Termin
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NZ581309A publication Critical patent/NZ581309A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/53—X and Y not being nitrogen atoms, e.g. N-sulfonylcarbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ581309A 2007-05-25 2008-05-21 Ion channel modulators and methods of use NZ581309A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93172207P 2007-05-25 2007-05-25
PCT/US2008/064314 WO2008147797A2 (en) 2007-05-25 2008-05-21 Ion channel modulators and methods of use

Publications (1)

Publication Number Publication Date
NZ581309A true NZ581309A (en) 2012-02-24

Family

ID=39876632

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ581309A NZ581309A (en) 2007-05-25 2008-05-21 Ion channel modulators and methods of use

Country Status (9)

Country Link
US (2) US8193194B2 (cg-RX-API-DMAC7.html)
EP (1) EP2158183A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010528035A (cg-RX-API-DMAC7.html)
CN (1) CN101687782A (cg-RX-API-DMAC7.html)
AU (1) AU2008256937A1 (cg-RX-API-DMAC7.html)
CA (1) CA2687764A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009012678A (cg-RX-API-DMAC7.html)
NZ (1) NZ581309A (cg-RX-API-DMAC7.html)
WO (1) WO2008147797A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2638784C1 (ru) * 2016-09-14 2017-12-15 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения миофасциальных болей в мышцах шеи по Гурову-Левину

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
CA2622076A1 (en) * 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
JP2009512717A (ja) * 2005-10-21 2009-03-26 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルを調節するための誘導体
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
JP2011503112A (ja) 2007-11-13 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物
MX2010005307A (es) * 2007-11-13 2010-07-28 Vertex Pharma Derivados heterociclicos como moduladores de canales de iones.
US20110031892A1 (en) * 2008-04-30 2011-02-10 Sharp Kabushiki Kaisha Lighting device and display device
NZ608116A (en) * 2010-09-13 2014-05-30 Novartis Ag Triazine-oxadiazoles
WO2012095781A1 (en) * 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
EP2773637B1 (en) 2011-10-31 2016-06-08 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
BR112015000187A2 (pt) 2012-07-06 2017-06-27 Genentech Inc benzamidas substituídas com n e métodos de uso das mesmas
AR094667A1 (es) 2013-01-31 2015-08-19 Vertex Pharma Piridonamidas como moduladores de canales de sodio
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
US9493429B2 (en) 2013-03-15 2016-11-15 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
MX2016006936A (es) * 2013-11-27 2016-10-05 Genentech Inc Benzamidas sustituidas y metodos para usarlas.
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
KR102364840B1 (ko) * 2014-11-05 2022-02-18 삼성전자주식회사 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법
BR112017024853A2 (pt) 2015-05-22 2018-08-07 Genentech Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um mamífero, para tratamento de prurido em um mamífero, para tratamento ou profilaxia e uso de um composto
US9771335B2 (en) * 2015-07-31 2017-09-26 The Johns Hopkins University Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
CN108495851A (zh) 2015-11-25 2018-09-04 基因泰克公司 取代的苯甲酰胺及其使用方法
US11014882B2 (en) * 2016-03-09 2021-05-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
PT3426243T (pt) 2016-03-09 2021-08-19 Raze Therapeutics Inc Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
JP2021514980A (ja) 2018-02-26 2021-06-17 ジェネンテック， インコーポレイテッド 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2024158872A1 (en) * 2023-01-25 2024-08-02 The Rockefeller University 1,3-indole-propanamide inhibitors of sars-cov-2 plpro/nsp3 and derivatives thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD9688A (cg-RX-API-DMAC7.html) *
US2411495A (en) * 1938-02-02 1946-11-19 Schering Corp Valuable derivatives of sulphonamides and a method of making the same
DE840241C (de) * 1938-02-03 1952-05-29 Schering Ag Verfahren zur Herstellung von Abkoemmlingen von Sulfonamiden
GB598472A (en) * 1943-11-05 1948-02-19 Geigy Ag J R Manufacture of para-aminobenzene sulphonacylamides
GB604259A (en) * 1944-12-28 1948-06-30 Geigy Ag J R Manufacture of 4-aminobenzenesulphonyl-ureas
US2907692A (en) * 1953-02-11 1959-10-06 Boehringer & Soehne Gmbh Composition for treating diabetes and a process of administering same
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
CH435298A (fr) * 1963-10-08 1967-05-15 Gevaert Photo Prod Nv Procédé de préparation de 3-acylamino-5-pyrazolones
BE666204A (cg-RX-API-DMAC7.html) * 1964-06-30
CH459222A (de) * 1965-10-27 1968-07-15 Sandoz Ag Verfahren zur Herstellung von neuen heterocyclischen Sulfonylharnstoff-Derivaten
RO62697A2 (fr) * 1974-05-04 1978-03-15 Sintofarm Intreprinderea Derives du 2,3-dihydro-1,3-benzoxazine-2,4-dione et procede de preparation
JPS6055062B2 (ja) * 1979-09-21 1985-12-03 塩野義製薬株式会社 Ｎ↑４−フエノキシアセチルスルフアニルアミド類および除草剤
US4461773A (en) * 1982-09-15 1984-07-24 E. I. Dupont De Nemours And Company P-Oxooxazolidinylbenzene compounds as antibacterial agents
DE3466986D1 (de) * 1983-02-04 1987-12-03 Ciba Geigy Ag N-phenylsulfonyl-n'-pyrimidinyl- and -triazinylurea
ATE84302T1 (de) 1988-10-20 1993-01-15 Ciba Geigy Ag Sulfamoylphenylharnstoffe.
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
JPH06135940A (ja) * 1992-10-22 1994-05-17 Mitsubishi Petrochem Co Ltd 新規なハロゲン化スルホンアミド誘導体およびそれを有効成分とする除草剤
CA2110524A1 (en) * 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
US5620997A (en) * 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
DE19621522A1 (de) * 1996-05-29 1997-12-04 Hoechst Schering Agrevo Gmbh Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung
JP3050126B2 (ja) * 1996-06-11 2000-06-12 日本製紙株式会社 感熱記録体
JP2000198272A (ja) * 1998-11-04 2000-07-18 Oji Paper Co Ltd 可逆性感熱記録体
CA2447671C (en) * 2001-05-18 2013-01-08 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
IL160253A0 (en) * 2001-08-09 2004-07-25 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003062209A2 (en) * 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
JP2003321460A (ja) * 2002-02-28 2003-11-11 Takeda Chem Ind Ltd アゾール化合物
RU2006106710A (ru) * 2003-08-05 2007-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Конденсированные пиримидиновые соединения в качестве ингибиторов потенциалозависимых ионных каналов
CA2539227A1 (en) * 2003-08-08 2005-02-17 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8759335B2 (en) 2004-01-30 2014-06-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
DE102004035132A1 (de) * 2004-07-20 2006-02-16 Bayer Cropscience Ag Insektizide Mittel auf Basis von ausgewählten Insektiziden und Safenern
UY29298A1 (es) * 2004-12-23 2006-05-31 Glaxo Group Ltd Compuestos
EP1891063B1 (en) 2005-05-10 2012-07-25 Vertex Pharmaceuticals, Inc. Bicyclic derivatives as modulators of ion channels
KR20080021030A (ko) 2005-05-16 2008-03-06 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 바이사이클릭 유도체
US7683066B2 (en) 2005-05-20 2010-03-23 Vertex Pharmaceuticals Incorporated Isoquinolines useful as modulators of ion channels
MX2007015726A (es) 2005-06-09 2008-03-04 Vertex Pharma Derivados de indano como moduladores de canales ionicos.
CA2622076A1 (en) 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
WO2007047474A2 (en) 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
JP2009512717A (ja) 2005-10-21 2009-03-26 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルを調節するための誘導体
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
TW200740803A (en) 2005-12-21 2007-11-01 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
AU2006336504C9 (en) 2005-12-28 2015-05-14 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
ES2580803T3 (es) 2006-04-07 2016-08-26 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de unión a ATP
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
MX2010005307A (es) 2007-11-13 2010-07-28 Vertex Pharma Derivados heterociclicos como moduladores de canales de iones.
JP2011503112A (ja) 2007-11-13 2011-01-27 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の処置のためのイオンチャンネルのモジュレーターとしての４（−３−（−２−（フェニル）モルホリノ）−２−オキソピロリジン−１−イル）−ｎ−（チアゾール−２−イル）ベンゼンスルホンアミド誘導体および関連化合物
SI2217572T1 (sl) 2007-11-16 2014-05-30 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
NZ703814A (en) 2008-02-28 2016-06-24 Vertex Pharma Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl) 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
WO2010002956A2 (en) 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2638784C1 (ru) * 2016-09-14 2017-12-15 Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" Способ лечения миофасциальных болей в мышцах шеи по Гурову-Левину

Also Published As

Publication number Publication date
CN101687782A (zh) 2010-03-31
WO2008147797A3 (en) 2009-07-09
MX2009012678A (es) 2012-09-20
US20080293737A1 (en) 2008-11-27
US8883766B2 (en) 2014-11-11
WO2008147797A2 (en) 2008-12-04
US8193194B2 (en) 2012-06-05
JP2010528035A (ja) 2010-08-19
US20120208790A1 (en) 2012-08-16
EP2158183A2 (en) 2010-03-03
CA2687764A1 (en) 2008-12-04
AU2008256937A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
US8883766B2 (en) Ion channel modulators and methods of use
US8236815B2 (en) Ion channel modulators and methods of uses
EP1891063B1 (en) Bicyclic derivatives as modulators of ion channels
US7989481B2 (en) Indane derivatives as modulators of ion channels
EP1888558B1 (en) Bicyclic derivatives as modulators of ion channels
NZ547109A (en) Benzimidazoles useful as modulators of ion channels
EP2220080B1 (en) Heterocyclic derivatives as modulators of ion channels
AU2007258313A1 (en) Thienopyrimidines useful as modulators of ion channels
EP1934191B1 (en) Biphenyl derivatives as modulators of voltage gated ion channels
JP2012149084A (ja) イオンチャネルのモジュレーターとして有用なキノリン誘導体
WO2006119451A1 (en) Pyrimidines and pyrazines useful as modulators of ion channels
EP1877381A1 (en) Pyridines useful as modulators of ion channels
JP2008540665A (ja) イオンチャネルのモジュレーターとして有用なビアリール
HK1139648A (en) Ion channel modulators and methods of use
HK1129096B (en) Compositions useful as inhibitors of voltage-gated sodium channels
HK1129096A1 (zh) 適用作電壓-門控鈉通道抑制劑的組合物

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3155030, VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MASSACHUSETTS 02210, US

Effective date: 20150127